AN UNBIASED VIEW OF ML-210

Phase III trials have recently been finished and published Phase II data display much greater efficacy for this triple therapy.42 Importantly, this combination of two correctors along with a promoter is effective in individuals heterozygous for p.Phe508del. The most effective suggest FEV1% improvements in this dose-ranging analyze were being thirte